Acrivon Therapeutics, Common Stock Alpha and Beta Analysis
| ACRV Stock | 1.23 0.07 6.03% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Acrivon Therapeutics, Common. It also helps investors analyze the systematic and unsystematic risks associated with investing in Acrivon Therapeutics, over a specified time horizon. Remember, high Acrivon Therapeutics,'s alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Acrivon Therapeutics,'s market risk premium analysis include:
Beta 1.76 | Alpha (1.61) | Risk 10.55 | Sharpe Ratio (0.16) | Expected Return (1.72) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Acrivon Therapeutics, Backtesting, Acrivon Therapeutics, Valuation, Acrivon Therapeutics, Correlation, Acrivon Therapeutics, Hype Analysis, Acrivon Therapeutics, Volatility, Acrivon Therapeutics, History and analyze Acrivon Therapeutics, Performance. Acrivon Therapeutics, Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Acrivon Therapeutics, market risk premium is the additional return an investor will receive from holding Acrivon Therapeutics, long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Acrivon Therapeutics,. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Acrivon Therapeutics,'s performance over market.| α | -1.61 | β | 1.76 |
Acrivon Therapeutics, expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Acrivon Therapeutics,'s Buy-and-hold return. Our buy-and-hold chart shows how Acrivon Therapeutics, performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Acrivon Therapeutics, Market Price Analysis
Market price analysis indicators help investors to evaluate how Acrivon Therapeutics, stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Acrivon Therapeutics, shares will generate the highest return on investment. By understating and applying Acrivon Therapeutics, stock market price indicators, traders can identify Acrivon Therapeutics, position entry and exit signals to maximize returns.
Acrivon Therapeutics, Return and Market Media
The median price of Acrivon Therapeutics, for the period between Thu, Mar 6, 2025 and Wed, Jun 4, 2025 is 1.64 with a coefficient of variation of 69.35. The daily time series for the period is distributed with a sample standard deviation of 1.77, arithmetic mean of 2.56, and mean deviation of 1.54. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Heres Why Acrivon Therapeutics, Inc. is Poised for a Turnaround After Losing -52.81 percent in 4 Weeks | 03/28/2025 |
2 | Insider Trading | 04/01/2025 |
3 | Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ... | 04/25/2025 |
4 | Disposition of 215283 shares by Perceptive Advisors Llc of Acrivon Therapeutics, at 1.56 subject to Rule 16b-3 | 04/28/2025 |
5 | Disposition of 250000 shares by Perceptive Advisors Llc of Acrivon Therapeutics, at 1.41 subject to Rule 16b-3 | 04/29/2025 |
6 | Disposition of 437881 shares by Perceptive Advisors Llc of Acrivon Therapeutics, at 1.41 subject to Rule 16b-3 | 04/30/2025 |
7 | Disposition of 298886 shares by Perceptive Advisors Llc of Acrivon Therapeutics, at 1.34 subject to Rule 16b-3 | 05/01/2025 |
8 | Heres Why Acrivon Therapeutics, Inc. Is a Great Buy the Bottom Stock Now | 05/05/2025 |
9 | Acrivon Therapeutics to Release Earnings on Tuesday | 05/06/2025 |
10 | Disposition of 558 shares by Miller Mary of Acrivon Therapeutics, at 7.87 subject to Rule 16b-3 | 05/08/2025 |
11 | Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights ... | 05/14/2025 |
12 | Acrivon Therapeutics GAAP EPS of -0.51 beats by 0.10 | 05/15/2025 |
13 | JonesResearch Downgrades Acrivon Therapeutics to Hold ACRV Stock News | 05/16/2025 |
14 | Disposition of 19904 shares by Blume-jensen Peter of Acrivon Therapeutics, at 1.15 subject to Rule 16b-3 | 05/21/2025 |
About Acrivon Therapeutics, Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Acrivon or other stocks. Alpha measures the amount that position in Acrivon Therapeutics, has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Current Ratio | 19.61 | 9.75 | 10.55 | 16.97 | Net Debt To EBITDA | 0.82 | 0.52 | 0.45 | 0.43 |
Acrivon Therapeutics, Upcoming Company Events
As portrayed in its financial statements, the presentation of Acrivon Therapeutics,'s financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Acrivon Therapeutics,'s leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Acrivon Therapeutics,'s public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Acrivon Therapeutics,. Please utilize our Beneish M Score to check the likelihood of Acrivon Therapeutics,'s management manipulating its earnings.
| 26th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Acrivon Therapeutics,
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Acrivon Stock Analysis
When running Acrivon Therapeutics,'s price analysis, check to measure Acrivon Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acrivon Therapeutics, is operating at the current time. Most of Acrivon Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Acrivon Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acrivon Therapeutics,'s price. Additionally, you may evaluate how the addition of Acrivon Therapeutics, to your portfolios can decrease your overall portfolio volatility.